Genetically modified pathogens play a pivotal role in modern vaccine development by allowing scientists to reduce pathogenicity while retaining an immune response-inducing capability. Through genetic engineering, certain genes responsible for causing illness are altered or removed, creating a weakened version of the pathogen. This modified pathogen, often used in live-attenuated vaccines, effectively mimics the infection process without causing disease. This approach enables a stronger, longer-lasting immune response compared to inactivated vaccines. Genetically modified pathogens are especially beneficial in creating vaccines for diseases like tuberculosis and malaria, where robust immune responses are necessary. Additionally, advancements in genetic engineering make it easier to scale vaccine production quickly, a crucial factor during epidemics when timely responses are needed to prevent widespread transmission.
Submit your abstract Today
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Prophylactic and Molecular Approaches for Mitigating Human Influenza A Viruses: i. Evaluating influenza Vaccine Effectiveness in the Older population ii. Down-regulation of influenza virus genes with novel siRNA-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : Development of a Novel Multi-component Vaccine to Address the Burden of Otitis Media in High-Risk Populations
Ayesha Zahid, Griffith University, Australia
Title : Targeting resistance: New 4-substituted pyrazolidine and isoxazolidine as antibiotics with interesting antimicrobial activities
Yousfi Tarek, Nationale Research for Biotechnology Research Center, Algeria
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Immunosuppression in COVID-19 Patients and Emerging Fungal Infections: Vaccines, Diagnosis and Strategies to Treat Comorbidities
K R Aneja, Kurukshetra University, India
Title : Immunogenicity and Cryo-EM structure of native-like HIV-1 Clade-C envelope trimers derived from a pediatric elite-neutralizer
Swarandeep Singh, All India Institute of Medical Sciences, India
Title : Why is the vaccine life-threatening if people get a fever after a COVID-19 vaccination
Yacob Mathai, Marma Health Centre, India
Title : Barriers to polio eradication in South Asia: A systematic review
Awranoos Ahadi, Bolan Medical College, Pakistan